Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market

Roche has reported a phase 3 win for sefaxersen in kidney disease, teeing up talks with regulators about the path to approval for the Ionis-partnered, would-be blockbuster candidate.